Dual galectin-8 and ALCAM silencing delays triple negative breast cancer progression

FERRAGUT, FÁTIMA; COLOMBO, LUCAS L.; CAGNONI, ALEJANDO J.; TRONCOSO, MARÍA F.; WOLFENSTEIN-TODEL, CARLOTA; SÁNCHEZ-TERRERO, CLARA; VANZULLI, SILVIA I.; RABINOVICH, GABRIEL A.; MARIÑO, KARINA V.; ELOLA, MARÍA T.

Simposio; Buenos Aires Breast Cancer Symposium; 2021

Triple-negative breast cancer (TNBC) comprises 10-15% of breast tumors, and lacks targeted therapy. Galectin-8 (Gal-8) is a tandem-repeat type galectin involved in cell adhesion and migration, angiogenesis and tumor progression. Here, we studied the tumorigenic properties of Gal-8 and its ligand ALCAM/CD166 in TNBC. We silenced both Gal-8 and ALCAM in MDA-MB-231 cells with specific (MDA-shGal8 and MDA-shALCAM, respectively) or scrambled shRNA lentiviral particles (MDA-shControl). Interestingly, both MDA-shALCAM (p